MedTrace Logo

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 813

Last updated 2019-06-13

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

semaglutide

One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly

DRUG

exenatide

One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-02
Primary Completion
2015-07-13
Completion
2015-07-13

Countries

  • United States
  • Argentina
  • Croatia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Puerto Rico
  • Serbia
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885208 on ClinicalTrials.gov